Compare BSTZ & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BSTZ | IMTX |
|---|---|---|
| Founded | 2019 | N/A |
| Country | United States | Germany |
| Employees | N/A | 407 |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.3B |
| IPO Year | N/A | N/A |
| Metric | BSTZ | IMTX |
|---|---|---|
| Price | $28.45 | $11.51 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $19.00 |
| AVG Volume (30 Days) | 209.7K | ★ 327.6K |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | ★ 8.31% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.71 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $25.91 |
| P/E Ratio | $39.44 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $18.67 | $4.93 |
| 52 Week High | $28.51 | $12.41 |
| Indicator | BSTZ | IMTX |
|---|---|---|
| Relative Strength Index (RSI) | 73.66 | 58.67 |
| Support Level | $20.98 | $8.97 |
| Resistance Level | N/A | $12.41 |
| Average True Range (ATR) | 0.74 | 0.51 |
| MACD | 0.16 | -0.02 |
| Stochastic Oscillator | 97.15 | 65.09 |
BlackRock Science and Technology Trust II is a non-diversified, closed-end management investment company. The trust's investment objectives are to provide total return and income through a combination of current income, current gains, and long-term capital appreciation. Its portfolio consists of Equity Securities, Options, Preferred Securities, Convertible Securities, Depositary Receipts, Non-U.S. Securities, Emerging Markets Investments, Restricted and Illiquid Investments, Private Company Investments, Corporate Bonds, and other investments. The trust seeks to Invest at least 80% of its total assets in equity securities issued by U.S. and non-U.S. science and technology companies in any market capitalization range from the development, advancement, and use of science and/or technology.
Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.